ReviewHuman cell2020
Current status and perspectives of patient-derived rare cancer models.
Review in Human cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Feasibility and barriers to rapid establishment of patient-derived primary osteosarcoma cell lines in clinical management.iScience · 2024Review
- Article
- CDK4/6 Inhibition With Lerociclib is a Potential Therapeutic Strategy for the Treatment of Pediatric Sarcomas.Journal of pediatric surgery · 2024Article
- Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials.Clinical trials (London, England) · 2024Review
- An Exploration of Organoid Technology: Present Advancements, Applications, and Obstacles.Current pharmaceutical biotechnology · 2024Review
- Review
- Applications of human organoids in the personalized treatment for digestive diseases.Signal transduction and targeted therapy · 2022Review
- Organoids: A New Chapter in Sarcoma Diagnosis and Treatment.International journal of molecular sciences · 2022Review
- Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.Human cell · 2022Article
- A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX).Journal of cancer research and clinical oncology · 2022Article
- Organoids.Nature reviews. Methods primers · 2022Article
- Establishment and characterization of a novel cell line, NCC-DDLPS2-C1, derived from a patient with dedifferentiated liposarcoma.Human cell · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Malignancies with extremely low incidences, such as less than 6 per 100,000 people annually, are defined as rare cancers. Approximately 200 malignancies are classified in this category, therefore the total number of patients with rare cancers is greater than that of patients with any single common cancer. However, because of the small numbers of patients, novel therapies have not been developed for individual rare cancers, and clinical outcomes remain dismal. Patient-derived cancer models are indispensable for both basic and pre-clinical studies, and their roles will increase in the era of post-genome medicine. Although patient-derived cancer models have long been used in oncology, they are not well developed for rare cancers. In the context of sarcoma, the presently available cell lines and xenograft models are limited and do not satisfy the needs of research. Indeed, the lack of effective therapies for rare cancers might be attributable to the paucity of adequate patient-derived cancer models for pre-clinical studies. To facilitate the establishment and availability of patient-derived rare cancer models, we need to create effective methods for model establishment, share the valuable clinical samples and established models, and implement guidelines to record the clinical data of donor patients and original tumors. Patient-derived rare cancer models are a public resource, and they should not be used exclusively but should rather be shared among the research community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.